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During the Phase III process development and tech transfer of a bispecific antibody project in Sanofi, many 
technical and logistical challenges were encountered for this cross-site collaboration project.  In particular, 
Phase III process development and tech transfer involves three different sites as sending and receiving units 
located in different continents using different scales of equipment.  Due to this constraint, additional 
considerations are required to address gaps between different small scale models prior to scale-up in order to 
de-risk the challenges that we may encounter during process transfer. Particularly, computational fluid dynamics 
(CFD) modeling and first principles calculation are used not only to support scale-up but also to bridge the 
difference between the small-scale models.  In addition to this logistical challenge, the team also systematically 
addressed some technical challenges in order to close several major manufacturability gaps between the Phase 
I/II and the Phase III processes. This poster summarizes our approach to resolve each of these challenges in 
order to collaboratively accomplish a successful tech transfer. 
 
